WO2011007324A1 - Pyridin-4-yl derivatives - Google Patents
Pyridin-4-yl derivatives Download PDFInfo
- Publication number
- WO2011007324A1 WO2011007324A1 PCT/IB2010/053224 IB2010053224W WO2011007324A1 WO 2011007324 A1 WO2011007324 A1 WO 2011007324A1 IB 2010053224 W IB2010053224 W IB 2010053224W WO 2011007324 A1 WO2011007324 A1 WO 2011007324A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- ethyl
- methoxy
- pyridin
- oxadiazol
- Prior art date
Links
- HNJOAIYFUCQZAA-UHFFFAOYSA-N Cc1n[o]c(C)n1 Chemical compound Cc1n[o]c(C)n1 HNJOAIYFUCQZAA-UHFFFAOYSA-N 0.000 description 2
- YVDWFZIVIIKYBQ-UHFFFAOYSA-N Cc1nnc(C)[o]1 Chemical compound Cc1nnc(C)[o]1 YVDWFZIVIIKYBQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Definitions
- the present invention relates to S1 P1/EDG1 receptor agonists of Formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions.
- the invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing a compound of the Formula (I), and their use as compounds improving vascular function and as immunomodulating agents, either alone or in combination with other active compounds or therapies.
- the human immune system is designed to defend the body against foreign microorganisms and substances that cause infection or disease.
- Complex regulatory mechanisms ensure that the immune response is targeted against the intruding substance or organism and not against the host. In some cases, these control mechanisms are unregulated and autoimmune responses can develop. A consequence of the uncontrolled inflammatory response is severe organ, cell, tissue or joint damage.
- Typical drugs in this class include azathioprine, chlorambucil, cyclophosphamide, cyclosporin, or methotrexate.
- Corticosteroids which reduce inflammation and suppress the immune response, may cause side effects when used in long term treatment.
- Nonsteroidal anti-inflammatory drugs NSAIDs
- Alternative treatments include agents that activate or block cytokine signaling.
- Orally active compounds with immunomodulating properties, without compromising immune responses and with reduced side effects would significantly improve current treatments of uncontrolled inflammatory diseases.
- Organ transplant recipients can experience some rejection even when they are taking immunosuppressive drugs. Rejection occurs most frequently in the first few weeks after transplantation, but rejection episodes can also happen months or even years after transplantation. Combinations of up to three or four medications are commonly used to give maximum protection against rejection while minimizing side effects. Current standard drugs used to treat the rejection of transplanted organs interfere with discrete intracellular pathways in the activation of T-type or B-type white blood cells.
- drugs examples include cyclosporin, daclizumab, basiliximab, everolimus, or FK506, which interfere with cytokine release or signaling; azathioprine or leflunomide, which inhibit nucleotide synthesis; or 15-deoxyspergualin, an inhibitor of leukocyte differentiation.
- the present invention provides novel compounds of Formula (I) that are agonists for the G protein-coupled receptor S1 P1/EDG1 and have a powerful and long-lasting immunomodulating effect which is achieved by reducing the number of circulating and infiltrating T- and B-lymphocytes, without affecting their maturation, memory, or expansion.
- the reduction of circulating T- / B-lymphocytes as a result of S1 P1/EDG1 agonism possibly in combination with the observed improvement of endothelial cell layer function associated with S1 P1/EDG1 activation, makes such compounds useful to treat uncontrolled inflammatory diseases and to improve vascular functionality.
- Prior art document WO 2008/029371 discloses compounds that act as S1 P1/EDG1 receptor agonists and show an immunomodulating effect as described above. Unexpectedly, it has been found that the compounds of the present invention have a reduced potential to constrict airway tissue/vessels when compared to compounds of the prior art document WO 2008/029371. The compounds of the present invention therefore demonstrate superiority with respect to their safety profile, e.g. a lower risk of bronchoconstriction.
- Figure 1 Structure of Examples of prior art document WO 2008/029371 , which are considered closest analogues to the compounds of the present invention.
- the compounds of Example 1 and 6 of the present invention show a significantly reduced potential to constrict rat trachea rings when compared to the compounds of prior art Examples 222 and 226 of WO 2008/029371 , respectively. Furthermore, the compounds of Example 1 and 6 of the present invention also show a reduced potential to constrict rat trachea rings when compared to the compounds of prior art Examples 196 and 204 of WO 2008/029371 , respectively.
- R 1 represents 3-pentyl and R 2 represents methoxy are superior compared to the closest prior art compounds of WO 2008/029371 , i.e.
- Example 3 of the present invention exhibits the same low potential to constrict rat trachea rings as its S-enantiomer, i.e. the compound of Example 2 of the present invention, indicating that the configuration at this position has no significant effect on trachea constriction.
- Example 21 of the present invention exhibits the same low potential to constrict rat trachea rings as present Example 2, which differs from Example 21 only by the linker A (forming a 5-pyridin-4-yl-[1 ,2,4]oxadiazole instead of a 3- pyridin-4-yl-[1 ,2,4]oxadiazole). This indicates that also the nature of the oxadiazole is not critical regarding trachea constriction.
- the compounds of the present invention can be utilized alone or in combination with standard drugs inhibiting T-cell activation, to provide a new immunomodulating therapy with a reduced propensity for infections when compared to standard immunosuppressive therapy. Furthermore, the compounds of the present invention can be used in combination with reduced dosages of traditional immunosuppressant therapies, to provide on the one hand effective immunomodulating activity, while on the other hand reducing end organ damage associated with higher doses of standard immunosuppressive drugs.
- the observation of improved endothelial cell layer function associated with S1 P1/EDG1 activation provides additional benefits of compounds to improve vascular function.
- nucleotide sequence and the amino acid sequence for the human S1 P1/EDG1 receptor are known in the art and are published in e.g.: HIa, T., and Maciag, T., J. Biol
- the invention relates to pyridine compounds of the Formula (I),
- R 1 represents 3-pentyl, 3-methyl-but-1-yl, cyclopentyl, or cyclohexyl;
- R 2 represents methoxy
- R 3 represents 2,3-dihydroxypropoxy, -OCH 2 -CH(OH)-CH 2 -NHCO-CH 2 OH, -OCH 2 -CH(OH)- CH 2 N(CHs)-CO-CH 2 OH, -NHSO 2 CH 3 , Or -NHSO 2 CH 2 CH 3 ;
- R 4 represents ethyl or chloro.
- ii) Another embodiment of the invention relates to pyridine derivatives according to embodiment i), wherein the stereocenter of the R 3 groups 2,3-dihydroxypropoxy, -OCH 2 - CH(OH)-CH 2 -NHCO-CH 2 OH, and -OCH 2 -CH(OH)-CH 2 N(CH 3 )-CO-CH 2 OH is in the S- configuration.
- iii) Another embodiment of the invention relates to pyridine derivatives according to embodiment i), wherein the stereocenter of the R 3 groups 2,3-dihydroxypropoxy, -OCH 2 - CH(OH)-CH 2 -NHCO-CH 2 OH, and -OCH 2 -CH(OH)-CH 2 N(CH 3 )-CO-CH 2 OH is in the R- configuration.
- iv) Another embodiment of the invention relates to pyridine derivatives according to any one of the embodiments i) to iii), wherein A represents
- Another embodiment of the invention relates to pyridine derivatives according to any one of the embodiments i) to iii), wherein A represents
- Another embodiment of the invention relates to pyridine derivatives according to any one of the embodiments i) to iii), wherein A represents vii) Another embodiment of the invention relates to pyridine derivatives according to any one of the embodiments i) to vi), wherein R 1 represents 3-pentyl. viii) Another embodiment of the invention relates to pyridine derivatives according to any one of the embodiments i) to vi), wherein R 1 represents 3-methyl-but-1-yl. ix) Another embodiment of the invention relates to pyridine derivatives according to any one of the embodiments i) to vi), wherein R 1 represents cyclopentyl.
- x) Another embodiment of the invention relates to pyridine derivatives according to any one of the embodiments i) to vi), wherein R 1 represents cyclohexyl.
- xi) Another embodiment of the invention relates to pyridine derivatives according to any one of the embodiments i) to x), wherein R 3 represents 2,3-dihydroxypropoxy.
- xii) Another embodiment of the invention relates to pyridine derivatives according to any oonnee ooff the embodiments i) to x), wherein R 3 represents -OCH 2 -CH(OH)-CH 2 -NHCO- CH 2 OH.
- xiii) Another embodiment of the invention relates to pyridine derivatives according to any oonnee ooff 1 the embodiments i) to x), wherein R 3 represents -OCH 2 -CH(OH)-CH 2 N(CH 3 )-CO-
- xiv) Another embodiment of the invention relates to pyridine derivatives according to any one of the embodiments i) to x), wherein R 3 represents -NHSO 2 CH 3 .
- xv) Another embodiment of the invention relates to pyridine derivatives according to any one of the embodiments i) to x), wherein R 3 represents -NHSO 2 CH 2 CH 3 .
- xvi) Another embodiment of the invention relates to pyridine derivatives according to any one of the embodiments i) to xv), wherein R 4 represents ethyl.
- xvii) Another embodiment of the invention relates to pyridine derivatives according to any one of the embodiments i) to xv), wherein R 4 represents chloro.
- the compounds of Formula (I) may contain one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms.
- the compounds of Formula (I) may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art.
- pharmaceutically acceptable salts refers to non-toxic, inorganic or organic acid and/or base addition salts. Reference can be made to "Salt selection for basic drugs", Int. J. Pharm. (1986), 33, 201-217.
- the present invention also includes isotopically labelled, especially 2 H (deuterium) labelled compounds of Formula (I), which compounds are identical to the compounds of Formula (I) except that one or more atoms have each been replaced by an atom having the same atomic number but an atomic mass different from the atomic mass usually found in nature.
- Isotopically labelled, especially 2 H (deuterium) labelled compounds of Formula (I) and salts thereof are within the scope of the present invention. Substitution of hydrogen with the heavier isotope 2 H (deuterium) may lead to greater metabolic stability, resulting e.g. in increased in vivo half-life or reduced dosage requirements, or may lead to reduced inhibition of cytochrome P450 enzymes, resulting e.g. in an improved safety profile.
- the compounds of Formula (I) are not isotopically labelled, or they are labelled only with one or more deuterium atoms. In a sub-embodiment, the compounds of Formula (I) are not isotopically labelled at all. Isotopically labelled compounds of Formula (I) may be prepared in analogy to the methods described hereinafter, but using the appropriate isotopic variation of suitable reagents or starting materials.
- pyridine compounds according to Formula (I) are selected from:
- pyridine compounds according to Formula (I) are further also selected from:
- the compounds of Formula (I) and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral or parenteral administration, and are suitable for decreasing the number of circulating lymphocytes and for the prevention and/or treatment of diseases or disorders associated with an activated immune system.
- compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21st Edition (2005), Part 5, "Pharmaceutical Manufacturing” [published by Lippincott Williams & Wilkins]) by bringing the described compounds of Formula (I) or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, pharmaceutically acceptable solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
- compositions comprising a compound of Formula (I) are useful for the prevention and/or treatment of diseases or disorders associated with an activated immune system.
- Such diseases or disorders associated with an activated immune system and to be prevented/treated with the compounds of Formula (I) are for example selected from the group consisting of rejection of transplanted organs, tissue or cells; graft-versus-host diseases brought about by transplantation; autoimmune syndromes including rheumatoid arthritis; systemic lupus erythematosus; antiphospholipid syndrome; Hashimoto's thyroiditis; lymphocytic thyroiditis; multiple sclerosis; myasthenia gravis; type I diabetes; uveitis; episcleritis; scleritis; Kawasaki's disease, uveo-retinitis; posterior uveitis; uveitis associated with Behcet's disease; uveomeningitis syndrome; allergic encephalomyelitis; chronic allograft vasculopathy; post-infectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis; inflammatory and hyperproliferative skin
- Formula (I) are selected from the group consisting of rejection of transplanted organs such as kidney, liver, heart, lung, pancreas, cornea, and skin; graft-versus-host diseases brought about by stem cell transplantation; autoimmune syndromes including rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases such as Crohn's disease and ulcerative colitis, psoriasis, psoriatic arthritis, thyroiditis such as Hashimoto's thyroiditis, uveo-retinitis; atopic diseases such as rhinitis, conjunctivitis, dermatitis; asthma; type I diabetes; postinfectious autoimmune diseases including rheumatic fever and post-infectious glomerulonephritis; solid cancers and tumor metastasis.
- transplanted organs such as kidney, liver, heart, lung, pancreas, cornea, and skin
- graft-versus-host diseases brought about by stem cell transplantation autoimmune syndromes including rheuma
- diseases or disorders to be treated and/or prevented with the compounds of Formula (I) are selected from the group consisting of rejection of transplanted organs selected from kidney, liver, heart and lung; graft-versus-host diseases brought about by stem cell transplantation; autoimmune syndromes selected from rheumatoid arthritis, multiple sclerosis, psoriasis, psoriatic arthritis, Crohn's disease, and Hashimoto's thyroiditis; and atopic dermatitis.
- diseases or disorders to be treated and/or prevented with the compounds of Formula (I) are selected from multiple sclerosis and psoriasis.
- the present invention also relates to a method for the prevention or treatment of a disease or disorder mentioned herein comprising administering to a subject a pharmaceutically active amount of a compound of Formula (I).
- compounds of the Formula (I) are also useful, in combination with one or several immunomodulating agents, for the prevention and/or treatment of the diseases and disorders mentioned herein.
- said agents are selected from the group consisting of immunosuppressants, corticosteroids, NSAI D's, cytotoxic drugs, adhesion molecule inhibitors, cytokines, cytokine inhibitors, cytokine receptor antagonists and recombinant cytokine receptors.
- the present invention also relates to the use of a compound of Formula (I) for the preparation of a pharmaceutical composition, optionally for use in combination with one or several immunomodulating agents, for the prevention or treatment of the diseases and disorders mentioned herein.
- the compounds of Formula (I) can be manufactured by the methods given below, by the methods given in the Examples or by analogous methods. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by a person skilled in the art by routine optimisation procedures.
- Compounds of the Formula (I) of the present invention can be prepared according to the general sequence of reactions outlined below. Only a few of the synthetic possibilities leading to compounds of Formula (I) are described.
- Compounds of Formula (I) which represent a 5-pyridin-4-yl-[1 ,2,4]oxadiazole derivative are prepared by reacting a compound of Structure 1 in a solvent such as toluene, pyridine, DMF, THF, dioxane, DME, etc.
- auxiliaries such as acids (e.g. TFA, acetic acid, HCI, etc.), bases (e.g. NaH, NaOAc, Na 2 CO 3 , K 2 CO 3 , NEt 3 , etc.), tetraalkylammonium salts, or water removing agents (e.g. oxalyl chloride, a carboxylic acid anhydride, POCI 3 , PCI 5 , P 4 O 10 , molecular sieves, Burgess reagent, etc.) (Lit.: e.g. A. R. Gangloff, J. Litvak, E. J. Shelton, D. Sperandio, V. R.
- Compounds of Structure 1 may be prepared by reacting a compound of Structure 2 with a compound of Structure 3 in a solvent such as DMF, THF, DCM, etc. in the presence of one or more coupling agents such as TBTU, DCC, EDC, HBTU, CDI, etc. and in the presence or absence of a base such as NEt 3 , DIPEA, NaH, K 2 CO 3 , etc. (Lit.: e.g. A. Hamze, J. -F. Hernandez, P. Fulcrand, J. Martinez, J. Org. Chem. 68 (2003) 7316-7321 ; and the literature cited above).
- a solvent such as DMF, THF, DCM, etc.
- one or more coupling agents such as TBTU, DCC, EDC, HBTU, CDI, etc.
- a base such as NEt 3 , DIPEA, NaH, K 2 CO 3 , etc.
- Compounds of Structure 3 and 4 may be prepared by reacting a compound of Structure 6 and 7, respectively, with hydroxylamine or one of its salts in a solvent such as MeOH, EtOH, pyridine, etc. in the presence or absence of a base such as Na 2 CO 3 , K 2 CO 3 , potassium tert.butylate, NEt 3 , etc. (Lit.: e.g. E. Meyer, A. C. Joussef, H. Gallardo, Synthesis 2003, 899-905, WO 2004/035538 (Merck & Co., Inc., USA)).
- a solvent such as MeOH, EtOH, pyridine, etc.
- a base such as Na 2 CO 3 , K 2 CO 3 , potassium tert.butylate, NEt 3 , etc.
- protecting groups are known to a person skilled in the art and include e.g. a benzyl or a trialkylsilyl group to protect an alcohol, a ketal to protect a diol, etc. These protecting groups may be employed according to standard methodology (e.g. T. W. Greene, P. G. M. Wuts, Protective Groups in Organic Synthesis, 3 rd Edition, Wiley New York, 1991 ; P. J. Kocienski, Protecting Groups, Thieme Stuttgart, 1994).
- the desired residues R 3 and R 4 may also be introduced in later steps that follow the coupling of the pyridine compounds of Structure 2 or 4 with the phenyl derivatives of Stucture 3 or 5 by using a suitable precursor of a compound of Structure 3 and 5.
- the phenyl compounds of Structure 3, 5 and 6 or their precursors are either commercially available or are prepared according to procedures known to a person skilled in the art.
- Compounds of Formula (I) which represent a 2-pyridin-4-yl-[1 ,3,4]oxadiazole are prepared similarly by reacting a compound of Structure 2 with hydrazine (by using a coupling reagent such as TBTU, DCC, EDC, HBTU, PyBOP, CDI, etc.) to form a compound of Structure 8 which is then coupled with a compound of Structure 5 to give a compound of Structure 9.
- a compound of Structure 9 can also be prepared by following the reverse reaction order i.e. by first coupling a compound of Stucture 5 with hydrazine followed by reacting the corresponding hydrazide intermediate with a compound of Structure 2.
- Dehydration of a compound of Structure 9 to form the desired 2-pyridin-4-yl-[1 ,3,4]oxadiazole derivative is affected by treating a compound of Structure 9 with a reagent such as POCI 3 , CCI 4 or CBr 4 in combination with PPh 3 , P 2 O 5 , Burgess reagent, etc. in a solvent such as toluene, MeCN, dioxane, THF, CHCI 3 , etc. at temperatures between 20 and 120 0 C in the presence or absence of microwave irradiation.
- a reagent such as POCI 3 , CCI 4 or CBr 4 in combination with PPh 3 , P 2 O 5 , Burgess reagent, etc.
- a solvent such as toluene, MeCN, dioxane, THF, CHCI 3 , etc. at temperatures between 20 and 120 0 C in the presence or absence of microwave irradiation.
- the compound of Structure 10 may then be reacted with the appropriate alkyl or cycloalkyl Zn reagent under Negishi conditions (Lit.: e.g. H. Matsushita, E. Negishi, J. Org. Chem. 47 (1982) 4161- 4165), with an appropriate alkyl or cycloalkyl Grignard reagent for instance in the presence of Fe(acac) 3 in a solvent such as THF, dioxane, DMF, NMP, etc., or combinations thereof, at temperatures ranging from -78 to 25°C under F ⁇ rstner conditions (Lit.: e.g. A. F ⁇ rstner, A. Leitner, M. Mendez, H.
- Negishi conditions Li.: e.g. H. Matsushita, E. Negishi, J. Org. Chem. 47 (1982) 4161- 4165
- an appropriate alkyl or cycloalkyl Grignard reagent
- the enantiomers can be separated using methods known to one skilled in the art: e.g. by formation and separation of diastereomeric salts or by HPLC over a chiral stationary phase such as a Regis Whelk-01 (R 1 R) (10 ⁇ m) column, a Daicel ChiralCel OD- H (5-10 ⁇ m) column, or a Daicel ChiralPak IA (10 ⁇ m) or AD-H (5 ⁇ m) column.
- a chiral stationary phase such as a Regis Whelk-01 (R 1 R) (10 ⁇ m) column, a Daicel ChiralCel OD- H (5-10 ⁇ m) column, or a Daicel ChiralPak IA (10 ⁇ m) or AD-H (5 ⁇ m) column.
- Typical conditions of chiral HPLC are an isocratic mixture of eluent A (EtOH, in presence or absence of an amine such as NEt 3 , diethylamine) and eluent B (hexane), at a flow rate of 0.8 to 150 mL/min.
- eluent A EtOH, in presence or absence of an amine such as NEt 3 , diethylamine
- eluent B hexane
- Compounds are purified by preparative HPLC (column: X-terra RP18, 50x19 mm, 5 ⁇ m, gradient: 10-95% MeCN in water containing 0.5 % of formic acid) or by MPLC (Labomatic MD-80-100 pump, Linear UVIS-201 detector, column: 350x18 mm, Labogel-RP-18-5s-100, gradient: 10% MeOH in water to 100% MeOH).
- the title compound and its ethyl ester are commercially available.
- the title compound is prepared from 3-ethyl-4-hydroxy-5-methyl-benzonitrile or from commercially available 2-ethyl-6-methyl-phenol following literature procedures (G. Trapani, A. Latrofa, M. Franco, C. Altomare, E. Sanna, M. Usala, G. Biggio, G. Liso, J. Med. Chem. 41 (1998) 1846-1854; A. K. Chakraborti, G. Kaur, Tetrahedron 55 (1999) 13265-13268; E. Meyer, A. C. Joussef, H.
- the mixture is cooled to 93 0 C and water (1250 mL) is added to obtain a solution.
- Ethyl acetate (1250 ml.) is added at 22-45 0 C and the layers are separated.
- the org. phase is washed with 10% aq. citric acid (2 x 500 mL) and water (500 ml_). The separated org.
- the org. layer is separated and washed with 20% aq. NaHS solution (1500 mL) and water (500 mL).
- the org. phase is then extracted three times with 0.5 N aq. NaOH (1000 mL), the aq. phase is acidified with 25 % aq. HCI (500 mL) and extracted twice with TBME (1000 mL).
- the mixture is stirred at rt for 1 h before it is diluted with EA and washed with water.
- the org. phase is separatered and concentrated.
- the remaining residue is dissolved in dioxane (10 ml.) and heated to 105 0 C for 18 h.
- the mixture is cooled to rt, concentrated and the crude product is purified on prep.
- the mixture is stirred at rt for 30 min, diluted with EA (100 ml.) and washed with brine.
- the org. extract is concentrated and the residue is dissolved in dioxane (50 ml_).
- the mixture is stirred at 100 0 C for 2 h before it is concentrated.
- the crude product is purified on prep.
- GTP ⁇ S binding assays are performed in 96 well microtiter plates (Nunc, 442587) in a final volume of 200 ⁇ l, using membrane preparations of CHO cells expressing recombinant human S1 P1 receptor. Assay conditions are 20 mM Hepes (Fluka, 54461 ), 100 mM NaCI (Fluka, 71378), 5 mM MgCI 2 (Fluka, 63064), 0.1% BSA (Calbiochem, 126609), 1 ⁇ M GDP (Sigma, G-7127), 2.5% DMSO (Fluka, 41644), 50 pM 35 S-GTP ⁇ S (Amersham Biosciences, SJ1320). The pH is 7.4.
- Test compounds are dissolved and diluted in 100% DMSO and pre-incubated at room temperature for 30 min in 150 ⁇ l of the above assay buffer, in the absence of 35 S-GTPyS. After addition of 50 ⁇ l of 35 S-GTPyS, the assay is incubated for 1 h at rt.
- the assay is terminated by transfer of the reaction mixture to a Multiscreen plate (Millipore, MAHFC1 H60) using a cell harvester from Packard Biosciences, and the plates are washed with ice-cold 10 mM Na 2 HPO 4 ZNaH 2 PO 4 (70%/30%), dried, sealed at the bottom and, after addition of 25 ⁇ l MicroScint20 (Packard Biosciences, order# 6013621 ), sealed on the top. Membrane-bound 35 S-GTP ⁇ S is measured with a TopCount from Packard Biosciences.
- EC 50 is the concentration of agonist inducing 50 % of the maximal specific 35 S-GTPyS binding. Specific binding is determined by subtracting non-specific binding from maximal binding. Maximal binding is the amount of cpm bound to the Multiscreen plate in the presence of 10 ⁇ M of S1 P. Non-specific binding is the amount of binding in the absence of an agonist in the assay. Agonistic activities (EC 50 values) of all exemplified compounds have been measured. EC 50 values of these compounds are displayed in Table 2.
- the efficacy of the compounds of Formula (I) is assessed by measuring the circulating lymphocytes after oral administration of 3 to 30 mg/kg of a compound of Formula (I) to normotensive male Wistar rats.
- the animals are housed in climate-controlled conditions with a 12 h-light/dark cycle, and have free access to normal rat chow and drinking water. Blood is collected before and 3, 6 and 24 h after drug administration. Full blood is subjected to hematology using Advia Hematology system (Bayer Diagnostics, Zurich, Switzerland).
- Table 3 shows the effect on lymphocyte counts 6 h after oral administration of 10 mg/kg of a compound of the present invention to normotensive male Wistar rats as compared to a group of animals treated with vehicle only. Lymphocyte counts 6 h after oral administration have been measured for 23 out of 30 exemplified compounds and are in the range of -42% to -80% with an average of -63%.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Description
Claims
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020127003855A KR101409131B1 (en) | 2009-07-16 | 2010-07-15 | Pyridin-4-yl derivatives |
AU2010272219A AU2010272219B2 (en) | 2009-07-16 | 2010-07-15 | Pyridin-4-yl derivatives |
EP10742897.1A EP2454255B1 (en) | 2009-07-16 | 2010-07-15 | Pyridin-4-yl derivatives as s1p1/edg1 agonists |
SG2012003372A SG178042A1 (en) | 2009-07-16 | 2010-07-15 | Pyridin-4-yl derivatives |
CA2767585A CA2767585C (en) | 2009-07-16 | 2010-07-15 | Pyridin-4-yl derivatives |
ES10742897.1T ES2441845T3 (en) | 2009-07-16 | 2010-07-15 | Pyridin-4-yl derivatives as S1P1 / EDG1 agonists |
MX2012000414A MX2012000414A (en) | 2009-07-16 | 2010-07-15 | Pyridin-4-yl derivatives. |
JP2012520145A JP5036923B1 (en) | 2009-07-16 | 2010-07-15 | Pyridin-4-yl derivative |
DK10742897.1T DK2454255T3 (en) | 2009-07-16 | 2010-07-15 | PYRIDIN-4 YLD DERIVATIVES AS S1P1 / EDG1 AGONISTS |
NZ598173A NZ598173A (en) | 2009-07-16 | 2010-07-15 | Pyridin-4-yl derivatives |
CN201080030606.XA CN102471328B (en) | 2009-07-16 | 2010-07-15 | Pyridin-4-yl derivatives |
RU2012105134/04A RU2547098C2 (en) | 2009-07-16 | 2010-07-15 | Pyrimidin-4-yl derivatives |
BR112012000763A BR112012000763B8 (en) | 2009-07-16 | 2010-07-15 | pyridin-4-yl derivative compounds, pharmaceutical composition, and uses of a compound |
SI201030453T SI2454255T1 (en) | 2009-07-16 | 2010-07-15 | Pyridin-4-yl derivatives as s1p1/edg1 agonists |
US13/383,619 US8658675B2 (en) | 2009-07-16 | 2010-07-15 | Pyridin-4-yl derivatives |
PL10742897T PL2454255T3 (en) | 2009-07-16 | 2010-07-15 | Pyridin-4-yl derivatives as s1p1/edg1 agonists |
IL217490A IL217490A (en) | 2009-07-16 | 2012-01-12 | Pyridin-4-yl derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments |
MA34631A MA33528B1 (en) | 2009-07-16 | 2012-02-14 | Bredin-4 derivatives to you |
ZA2012/01125A ZA201201125B (en) | 2009-07-16 | 2012-02-15 | Pyridin-4-yl derivatives |
HK12111159.0A HK1170479A1 (en) | 2009-07-16 | 2012-11-06 | Pyridin-4-yl derivatives as s1p1/edg1 agonists |
HRP20140098AT HRP20140098T1 (en) | 2009-07-16 | 2014-02-04 | Pyridin-4-yl derivatives as s1p1/edg1 agonists |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB2009053089 | 2009-07-16 | ||
IBPCT/IB2009/053089 | 2009-07-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011007324A1 true WO2011007324A1 (en) | 2011-01-20 |
Family
ID=42734812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2010/053224 WO2011007324A1 (en) | 2009-07-16 | 2010-07-15 | Pyridin-4-yl derivatives |
Country Status (27)
Country | Link |
---|---|
US (1) | US8658675B2 (en) |
EP (1) | EP2454255B1 (en) |
JP (1) | JP5036923B1 (en) |
KR (1) | KR101409131B1 (en) |
CN (1) | CN102471328B (en) |
AR (1) | AR077413A1 (en) |
AU (1) | AU2010272219B2 (en) |
BR (1) | BR112012000763B8 (en) |
CA (1) | CA2767585C (en) |
CY (1) | CY1114759T1 (en) |
DK (1) | DK2454255T3 (en) |
ES (1) | ES2441845T3 (en) |
HK (1) | HK1170479A1 (en) |
HR (1) | HRP20140098T1 (en) |
IL (1) | IL217490A (en) |
MA (1) | MA33528B1 (en) |
MX (1) | MX2012000414A (en) |
MY (1) | MY153617A (en) |
NZ (1) | NZ598173A (en) |
PL (1) | PL2454255T3 (en) |
PT (1) | PT2454255E (en) |
RU (1) | RU2547098C2 (en) |
SG (1) | SG178042A1 (en) |
SI (1) | SI2454255T1 (en) |
TW (1) | TWI410421B (en) |
WO (1) | WO2011007324A1 (en) |
ZA (1) | ZA201201125B (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012098505A1 (en) * | 2011-01-19 | 2012-07-26 | Actelion Pharmaceuticals Ltd | 2-methoxy-pyridin-4-yl derivatives |
US8410151B2 (en) | 2008-03-07 | 2013-04-02 | Actelion Pharmaceuticals Ltd | Aminomethyl benzene derivatives |
US8580824B2 (en) | 2006-09-07 | 2013-11-12 | Actelion Pharmaceuticals Ltd. | Pyridin-4-yl derivatives as immunomodulating agents |
US8592460B2 (en) | 2007-03-16 | 2013-11-26 | Actelion Pharmaceuticals Ltd. | Amino-pyridine derivatives as S1P1 /EDG1 receptor agonists |
WO2013175397A1 (en) | 2012-05-22 | 2013-11-28 | Actelion Pharmaceuticals Ltd | New process for the preparation of 2-cyclopentyl-6-methoxy-isonicotinic acid |
WO2016184939A1 (en) * | 2015-05-20 | 2016-11-24 | Actelion Pharmaceuticals Ltd | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
US9617250B2 (en) | 2013-03-15 | 2017-04-11 | Actelion Pharmaceuticals Ltd. | Pyridin-4-yl derivatives |
CN109369620A (en) * | 2018-12-22 | 2019-02-22 | 山东大学 | Pyridine compounds and their and preparation method thereof and anti-gastric cancer application |
WO2021084068A1 (en) | 2019-10-31 | 2021-05-06 | Idorsia Pharmaceuticals Ltd | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
WO2021148314A1 (en) | 2020-01-20 | 2021-07-29 | Idorsia Pharmaceuticals Ltd | Accelerated elimination of (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
WO2021157682A1 (en) | 2020-02-06 | 2021-08-12 | 田辺三菱製薬株式会社 | Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome |
US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
WO2024056631A1 (en) | 2022-09-14 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | S1p 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE502938T1 (en) * | 2007-08-17 | 2011-04-15 | Actelion Pharmaceuticals Ltd | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS |
JP5517944B2 (en) * | 2007-11-01 | 2014-06-11 | アクテリオン ファーマシューティカルズ リミテッド | Novel pyrimidine derivatives |
ES2389042T3 (en) * | 2008-03-06 | 2012-10-22 | Actelion Pharmaceuticals Ltd. | Pyridine compounds |
NZ588438A (en) * | 2008-03-07 | 2012-05-25 | Actelion Pharmaceuticals Ltd | Pyridin-2-yl oxadiazole derivatives as immunomodulating agents |
EP3590929B1 (en) * | 2017-02-28 | 2021-09-15 | Medshine Discovery Inc. | Spiro compound and use thereof |
CN107382965A (en) * | 2017-08-14 | 2017-11-24 | 河南科技大学第附属医院 | The synthetic method of the receptor stimulating agent drug molecules of new S1P 1 with antitumor activity |
CN107445941A (en) * | 2017-08-14 | 2017-12-08 | 河南科技大学第附属医院 | The preparation method and application of triazole compound with immunosuppressive activity |
CN107311994A (en) * | 2017-08-14 | 2017-11-03 | 淄博职业学院 | A kind of novel method for synthesizing of the receptor stimulating agent drug molecules of S1P 1 |
EP4116294A1 (en) * | 2020-03-04 | 2023-01-11 | Helioeast Pharmaceutical Co., Ltd. | Benzo 2-azaspiro[4.4]nonane compound and use thereof |
JP2024510647A (en) * | 2021-04-09 | 2024-03-08 | ヒーリオイースト ファーマシューティカル カンパニー リミテッド | Oxadiazole-substituted spirocyclic compounds and their uses |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991015583A1 (en) | 1990-04-05 | 1991-10-17 | The American National Red Cross | A protein family related to immediate-early protein expressed by human endothelial cells during differentiation |
WO1999046277A1 (en) | 1998-03-09 | 1999-09-16 | Smithkline Beecham Corporation | HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE |
WO2004035538A1 (en) | 2002-10-15 | 2004-04-29 | Merck & Co., Inc. | Process for making azetidine-3-carboxylic acid |
WO2008029371A1 (en) | 2006-09-07 | 2008-03-13 | Actelion Pharmaceuticals Ltd | Pyridin-4-yl derivatives as immunomodulating agents |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL31990A (en) | 1968-04-26 | 1974-05-16 | Chinoin Gyogyszer Es Vegyeszet | Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same |
CA2051494C (en) | 1990-09-20 | 2006-03-14 | Robert J. Dinerstein | 1-aryl-3-pyridinyl-2-propene-1-ones as calcium uptake inhibitors |
DE4429465A1 (en) | 1994-08-19 | 1996-02-22 | Bayer Ag | Process for the preparation of 2-halopyridine aldehydes and new 2-halopyridine aldehydes |
DE19904389A1 (en) | 1999-02-04 | 2000-08-10 | Bayer Ag | Use of substituted isoxazolecarboxylic acids and derivatives and new substances |
CZ2002599A3 (en) | 1999-08-19 | 2002-06-12 | Nps Pharmaceuticals Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
ES2292830T3 (en) | 2001-02-21 | 2008-03-16 | Astrazeneca Ab | HETEROPOLICICLIC COMPOUNDS AND THEIR USE AS ANTAGONISTS OF THE METABOTROPIC GLUTAMATE RECEIVER. |
CA2472715A1 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Edg receptor agonists |
DE60330047D1 (en) | 2002-01-18 | 2009-12-24 | Merck & Co Inc | "n-(benzyl)aminoalkyl carboxylate, phosphinate, phosphonate und tetrazole als edg rezeptoragonisten" |
CA2488117A1 (en) | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
DE10237883A1 (en) | 2002-08-19 | 2004-03-04 | Merckle Gmbh Chem.-Pharm. Fabrik | Substituted isoxazole derivatives and their use in pharmacy |
RU2331639C2 (en) * | 2002-08-23 | 2008-08-20 | Райджел Фармасьютикалз, Инк. | Pyridyl-substituted heterocycles, suitable for treatment or prevention of infections, caused by hepatitis c virus |
US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
CA2524867A1 (en) | 2003-05-15 | 2004-12-02 | Merck & Co., Inc. | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
WO2005014525A2 (en) | 2003-08-12 | 2005-02-17 | Mitsubishi Pharma Corporation | Bi-aryl compound having immunosuppressive activity |
EP1670463A2 (en) | 2003-10-01 | 2006-06-21 | Merck & Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
EP1697333A4 (en) * | 2003-12-17 | 2009-07-08 | Merck & Co Inc | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
US8022063B2 (en) | 2004-05-29 | 2011-09-20 | 7Tm Pharma A/S | CRTH2 receptor ligands for medicinal uses |
WO2006010379A1 (en) | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
AU2005299851B2 (en) | 2004-10-22 | 2011-03-17 | Merck Sharp & Dohme Corp. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists |
WO2006064757A1 (en) | 2004-12-13 | 2006-06-22 | Ono Pharmaceutical Co., Ltd. | Aminocarboxylic acid derivative and medicinal use thereof |
JP5072825B2 (en) | 2005-03-23 | 2012-11-14 | アクテリオン ファーマシューティカルズ リミテッド | Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists |
NZ562562A (en) | 2005-03-23 | 2010-11-26 | Actelion Pharmaceuticals Ltd | Hydrogenated benzo(C)thiophene derivatives as immunomodulators |
BRPI0609665A2 (en) | 2005-03-23 | 2010-04-20 | Actelion Pharmaceuticals Ltd | compound, pharmaceutical composition, and use of a compound |
EP1874772A1 (en) | 2005-04-05 | 2008-01-09 | Pharmacopeia, Inc. | Purine and imidazopyridine derivatives for immunosuppression |
CA2605594A1 (en) | 2005-04-22 | 2006-11-02 | Daiichi Sankyo Company, Limited | Heterocyclic compound |
MX2007013263A (en) | 2005-04-26 | 2008-01-22 | Neurosearch As | Novel oxadiazole derivatives and their medical use. |
BRPI0612028A2 (en) | 2005-06-08 | 2010-10-13 | Novartis Ag | polycyclic oxadiazoles or isodiazoles and their use as s1p receptor ligands |
US20070043104A1 (en) | 2005-06-10 | 2007-02-22 | Luthman Ingrid K | UII-modulating compounds and their use |
JP2008546758A (en) | 2005-06-24 | 2008-12-25 | アクテリオン ファーマシューティカルズ リミテッド | New thiophene derivatives |
WO2007001973A1 (en) | 2005-06-28 | 2007-01-04 | Astrazeneca Ab | New use |
AR057894A1 (en) | 2005-11-23 | 2007-12-26 | Actelion Pharmaceuticals Ltd | THIOPHEN DERIVATIVES |
TWI404706B (en) | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | Novel thiophene derivatives |
EP1979345B1 (en) | 2006-01-24 | 2009-11-04 | Actelion Pharmaceuticals Ltd. | Novel pyridine derivatives |
GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
WO2007098474A1 (en) | 2006-02-21 | 2007-08-30 | University Of Virginia Patent Foundation | Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as s1p receptor agonists |
RS20080525A (en) | 2006-05-09 | 2009-09-08 | Pfizer Products Inc., | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
AR061841A1 (en) | 2006-09-07 | 2008-09-24 | Actelion Pharmaceuticals Ltd | DERIVATIVES OF THIOFEN-OXADIAZOLS, AGONISTS OF THE S1P1 / EDG1 RECEPTOR, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USES AS IMMUNOMODULATING AGENTS. |
KR101454937B1 (en) | 2006-09-08 | 2014-10-27 | 액테리온 파마슈티칼 리미티드 | Pyridine-3-yl derivatives as immunomodulating agents |
RU2442780C2 (en) | 2006-09-21 | 2012-02-20 | Актелион Фармасьютиклз Лтд | Phenyl derivatives and their application as immunomodulators |
BRPI0717656A2 (en) | 2006-09-29 | 2014-04-29 | Novartis Ag | OXADIAZOL DIARYL DERIVATIVES |
JP2008120794A (en) | 2006-10-16 | 2008-05-29 | Daiichi Sankyo Co Ltd | Pharmaceutical composition containing heterocyclic compound |
EP2109364A4 (en) | 2006-12-15 | 2010-04-14 | Abbott Lab | Novel oxadiazole compounds |
US20110207704A1 (en) | 2006-12-15 | 2011-08-25 | Abbott Laboratories | Novel Oxadiazole Compounds |
WO2008091967A1 (en) | 2007-01-26 | 2008-07-31 | Smithkline Beecham Corporation | Chemical compounds |
NZ580454A (en) * | 2007-03-16 | 2011-05-27 | Actelion Pharmaceuticals Ltd | Amino- pyridine derivatives as s1p1 /edg1 receptor agonists |
ATE502938T1 (en) | 2007-08-17 | 2011-04-15 | Actelion Pharmaceuticals Ltd | PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS |
AU2008306886B2 (en) | 2007-10-04 | 2014-01-16 | Merck Serono S.A. | Oxadiazole diaryl compounds |
EA201070422A1 (en) | 2007-10-04 | 2010-12-30 | Мерк Сероно С.А. | OXADIAZOL DERIVATIVES |
JP5517944B2 (en) * | 2007-11-01 | 2014-06-11 | アクテリオン ファーマシューティカルズ リミテッド | Novel pyrimidine derivatives |
AU2008326184A1 (en) | 2007-11-08 | 2009-05-14 | Pfizer Inc. | Cyclobutyl carboxylic acid derivatives |
CA2706834A1 (en) | 2007-12-10 | 2009-06-18 | Actelion Pharmaceuticals Ltd | Thiophene derivatives as agonists of s1p1/edg1 |
CN101965346A (en) | 2008-03-06 | 2011-02-02 | 埃科特莱茵药品有限公司 | Novel pyrimidine-pyridine derivatives |
ES2389042T3 (en) | 2008-03-06 | 2012-10-22 | Actelion Pharmaceuticals Ltd. | Pyridine compounds |
NZ588438A (en) | 2008-03-07 | 2012-05-25 | Actelion Pharmaceuticals Ltd | Pyridin-2-yl oxadiazole derivatives as immunomodulating agents |
ES2389469T3 (en) | 2008-03-07 | 2012-10-26 | Actelion Pharmaceuticals Ltd. | Novel derivatives of aminomethylbenzene |
MY172105A (en) | 2008-05-14 | 2019-11-14 | Scripps Research Inst | Novel modulators of sphingosine phosphate receptors |
UY32734A (en) | 2009-06-26 | 2010-11-30 | Glaxo Group Ltd | 1-PHOSPHATE RECEPTOR AGONIST COMPOUNDS |
-
2010
- 2010-07-15 KR KR1020127003855A patent/KR101409131B1/en active IP Right Grant
- 2010-07-15 JP JP2012520145A patent/JP5036923B1/en active Active
- 2010-07-15 CN CN201080030606.XA patent/CN102471328B/en active Active
- 2010-07-15 TW TW099123317A patent/TWI410421B/en active
- 2010-07-15 SG SG2012003372A patent/SG178042A1/en unknown
- 2010-07-15 AR ARP100102565A patent/AR077413A1/en active IP Right Grant
- 2010-07-15 EP EP10742897.1A patent/EP2454255B1/en active Active
- 2010-07-15 CA CA2767585A patent/CA2767585C/en active Active
- 2010-07-15 PL PL10742897T patent/PL2454255T3/en unknown
- 2010-07-15 MY MYPI2012000167A patent/MY153617A/en unknown
- 2010-07-15 US US13/383,619 patent/US8658675B2/en active Active
- 2010-07-15 SI SI201030453T patent/SI2454255T1/en unknown
- 2010-07-15 AU AU2010272219A patent/AU2010272219B2/en active Active
- 2010-07-15 ES ES10742897.1T patent/ES2441845T3/en active Active
- 2010-07-15 PT PT107428971T patent/PT2454255E/en unknown
- 2010-07-15 MX MX2012000414A patent/MX2012000414A/en active IP Right Grant
- 2010-07-15 RU RU2012105134/04A patent/RU2547098C2/en active
- 2010-07-15 WO PCT/IB2010/053224 patent/WO2011007324A1/en active Application Filing
- 2010-07-15 NZ NZ598173A patent/NZ598173A/en unknown
- 2010-07-15 DK DK10742897.1T patent/DK2454255T3/en active
- 2010-07-15 BR BR112012000763A patent/BR112012000763B8/en active IP Right Grant
-
2012
- 2012-01-12 IL IL217490A patent/IL217490A/en active IP Right Grant
- 2012-02-14 MA MA34631A patent/MA33528B1/en unknown
- 2012-02-15 ZA ZA2012/01125A patent/ZA201201125B/en unknown
- 2012-11-06 HK HK12111159.0A patent/HK1170479A1/en unknown
-
2014
- 2014-01-16 CY CY20141100036T patent/CY1114759T1/en unknown
- 2014-02-04 HR HRP20140098AT patent/HRP20140098T1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991015583A1 (en) | 1990-04-05 | 1991-10-17 | The American National Red Cross | A protein family related to immediate-early protein expressed by human endothelial cells during differentiation |
WO1999046277A1 (en) | 1998-03-09 | 1999-09-16 | Smithkline Beecham Corporation | HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE |
WO2004035538A1 (en) | 2002-10-15 | 2004-04-29 | Merck & Co., Inc. | Process for making azetidine-3-carboxylic acid |
WO2008029371A1 (en) | 2006-09-07 | 2008-03-13 | Actelion Pharmaceuticals Ltd | Pyridin-4-yl derivatives as immunomodulating agents |
Non-Patent Citations (23)
Title |
---|
"Salt selection for basic drugs", INT. J. PHARM., vol. 33, 1986, pages 201 - 217 |
A. FURSTNER; A. LEITNER, ANGEW. CHEM., vol. 114, 2002, pages 632 - 635 |
A. FÜRSTNER; A. LEITNER; M. MENDEZ; H. KRAUSE, J. AM. CHEM. SOC., vol. 124, 2002, pages 13856 - 13863 |
A. HAMZE; J.-F. HERNANDEZ; P. FULCRAND; J. MARTINEZ, J. ORG. CHEM., vol. 68, 2003, pages 7316 - 7321 |
A. K. CHAKRABORTI; G. KAUR, TETRAHEDRON, vol. 55, 1999, pages 13265 - 13268 |
A. R. GANGLOFF; J. LITVAK; E. J. SHELTON; D. SPERANDIO; V. R. WANG; K. D. RICE, TETRAHEDRON LETT., vol. 42, 2001, pages 1441 - 1443 |
B. KABOUDIN; K. NAVAEE, HETEROCYCLES, vol. 60, 2003, pages 2287 - 2292 |
B. ROTH ET AL., J. MED. CHEM., vol. 31, 1988, pages 122 - 129 |
BUZARD D J ET AL: "Recent progress in the development of selective S1P1 receptor agonists for the treatment of inflammatory and autoimmune disorders", EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 18, no. 10, 1 October 2008 (2008-10-01), INFORMA HEALTHCARE, GB, pages 1141 - 1159, XP002525321, ISSN: 1354-3776, DOI: 10.1517/13543776.18.10.1141 * |
C. T. BRAIN; J. M. PAUL; Y. LOONG; P. J. OAKLEY, TETRAHEDRON LETT., vol. 40, 1999, pages 3275 - 3278 |
E. MEYER; A. C. JOUSSEF; H. GALLARDO, SYNTHESIS, 2003, pages 899 - 905 |
E. O. JOHN; J. M. SHREEVE, INORGANIC CHEMISTRY, vol. 27, 1988, pages 3100 - 3104 |
F. KERINS; D. F. O'SHEA, J. ORG. CHEM., vol. 67, 2002, pages 4968 - 4971 |
G. TRAPANI; A. LATROFA; M. FRANCO; C. ALTOMARE; E. SANNA; M. USALA; G. BIGGIO; G. LISO, J. MED. CHEM., vol. 41, 1998, pages 1846 - 1854 |
H. DOUCET, EUR. J. ORG. CHEM., 2008, pages 2013 - 2030 |
H. MATSUSHITA; E. NEGISHI, J. ORG. CHEM., vol. 47, 1982, pages 4161 - 4165 |
HLA, T.; MACIAG, T., J. BIOL CHEM., vol. 265, 1990, pages 9308 - 9313 |
M. A. GARCIA; S. MARTIN-SANTAMARIA; M. CACHO; F. MORENO DE LA LLAVE; M. JULIAN; A. MARTINEZ; B. DE PASCUAL-TERESA; A. RAMOS, J. MED. CHEM., vol. 48, 2005, pages 4068 - 4075 |
N. WILD; U. GROTH, EUR. J. ORG. CHEM., 2003, pages 4445 - 4449 |
R. F. POULAIN; A. L. TARTAR; B. P. DÉPREZ, TETRAHEDRON LETT., vol. 42, 2001, pages 1495 - 1498 |
R. M. SRIVASTAVA; F. J. S. OLIVEIRA; D. S. MACHADO; R. M. SOUTO-MAIOR, SYNTHETIC COMMUN., vol. 29, 1999, pages 1437 - 1450 |
SCHÜRER ET AL: "Ligand-Binding Pocket Shape Differences between Sphingosine 1-Phosphate (S1P) Receptors S1P1 and S1P3 Determine Efficiency of Chemical Probe Identification by Ultrahigh-Throughput Screening", ACS CHEMICAL BIOLOGY, vol. 3, no. 8, 1 July 2008 (2008-07-01), pages 486 - 498, XP002602034 * |
T. SUZUKI; K. LWAOKA; N. LMANISHI; Y. NAGAKURA; K. MIYTA; H. NAKAHARA; M. OHTA; T. MASE, CHEM. PHARM. BULL., vol. 47, 1999, pages 120 - 122 |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8580824B2 (en) | 2006-09-07 | 2013-11-12 | Actelion Pharmaceuticals Ltd. | Pyridin-4-yl derivatives as immunomodulating agents |
US8592460B2 (en) | 2007-03-16 | 2013-11-26 | Actelion Pharmaceuticals Ltd. | Amino-pyridine derivatives as S1P1 /EDG1 receptor agonists |
US8410151B2 (en) | 2008-03-07 | 2013-04-02 | Actelion Pharmaceuticals Ltd | Aminomethyl benzene derivatives |
WO2012098505A1 (en) * | 2011-01-19 | 2012-07-26 | Actelion Pharmaceuticals Ltd | 2-methoxy-pyridin-4-yl derivatives |
WO2013175397A1 (en) | 2012-05-22 | 2013-11-28 | Actelion Pharmaceuticals Ltd | New process for the preparation of 2-cyclopentyl-6-methoxy-isonicotinic acid |
CN104321311A (en) * | 2012-05-22 | 2015-01-28 | 埃科特莱茵药品有限公司 | New process for the preparation of 2-cyclopentyl-6-methoxy-isonicotinic acid |
US9617250B2 (en) | 2013-03-15 | 2017-04-11 | Actelion Pharmaceuticals Ltd. | Pyridin-4-yl derivatives |
TWI711609B (en) * | 2015-05-20 | 2020-12-01 | 瑞士商愛杜西亞製藥有限公司 | Crystalline forms |
US11390615B2 (en) | 2015-05-20 | 2022-07-19 | Idorsia Pharmaceuticals Ltd | Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenox |
US11834443B2 (en) | 2015-05-20 | 2023-12-05 | Idorsia Pharmaceuticals Ltd | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
US10385043B2 (en) | 2015-05-20 | 2019-08-20 | Idorsia Pharmaceuticals Ltd | Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
AU2016263472B2 (en) * | 2015-05-20 | 2020-02-27 | Idorsia Pharmaceuticals Ltd | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
EA035133B1 (en) * | 2015-05-20 | 2020-04-30 | Идорсия Фармасьютиклз Лтд | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}propane-1,2-diol |
US10836754B2 (en) | 2015-05-20 | 2020-11-17 | Idorsia Pharmaceuticals Ltd | Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
WO2016184939A1 (en) * | 2015-05-20 | 2016-11-24 | Actelion Pharmaceuticals Ltd | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
KR102220848B1 (en) * | 2015-05-20 | 2021-02-26 | 이도르시아 파마슈티컬스 리미티드 | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
KR20180005252A (en) * | 2015-05-20 | 2018-01-15 | 이도르시아 파마슈티컬스 리미티드 | Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
CN109369620A (en) * | 2018-12-22 | 2019-02-22 | 山东大学 | Pyridine compounds and their and preparation method thereof and anti-gastric cancer application |
WO2021084068A1 (en) | 2019-10-31 | 2021-05-06 | Idorsia Pharmaceuticals Ltd | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
WO2021148314A1 (en) | 2020-01-20 | 2021-07-29 | Idorsia Pharmaceuticals Ltd | Accelerated elimination of (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol |
WO2021157682A1 (en) | 2020-02-06 | 2021-08-12 | 田辺三菱製薬株式会社 | Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome |
EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
WO2023135207A1 (en) | 2022-01-13 | 2023-07-20 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
WO2024056631A1 (en) | 2022-09-14 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | S1p 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2454255B1 (en) | Pyridin-4-yl derivatives as s1p1/edg1 agonists | |
EP2069322B1 (en) | Thiophene derivatives as s1p1/edg1 receptor agonists | |
EP2217594B1 (en) | Novel pyrimidine derivatives | |
EP2252609B1 (en) | Pyridin-2-yl derivatives as immunomodulating agents | |
EP2262799B1 (en) | Pyridine compounds | |
IL197394A (en) | Pyridin-3-yl derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments for treating or preventing diseases or disorders associated with the immune system | |
EP2069336A1 (en) | Pyridin-4-yl derivatives as immunomodulating agents | |
WO2014141171A1 (en) | Pyridin-4-yl derivatives | |
US9133179B2 (en) | 2-methoxy-pyridin-4-yl-derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080030606.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10742897 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010742897 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/000414 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2767585 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 217490 Country of ref document: IL Ref document number: 13383619 Country of ref document: US Ref document number: 12012500081 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012520145 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1201000128 Country of ref document: TH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1244/CHENP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010272219 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 20127003855 Country of ref document: KR Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012000763 Country of ref document: BR Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012105134 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2010272219 Country of ref document: AU Date of ref document: 20100715 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112012000763 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120112 |